A treatment for allergic rhinitis: a view on the role of levocetirizine

Authors: Holgate, Stephen1; Powell, Richard2; Jenkins, Maureen3; Ali, Omar4

Source: Current Medical Research and Opinion, Volume 21, Number 7, July 2005 , pp. 1099-1106(8)

Publisher: LibraPharm

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background: Allergic rhinitis is a significant public health concern in many developed countries. However, despite evidence for a significant impact on patients' quality of life (QoL) including sleep disruption and reduced daytime performance, allergic rhinitis remains under-managed and hence poorly controlled. This is largely owing to lack of knowledge about, and poor adherence to, established treatment guidelines.

Scope: The panel considered available evidence and focused on four published studies on the second-generation antihistamine, levocetirizine. Three of these studies explored the clinical impact of levocetirizine in a broad range of different clinical settings.

Findings: Levocetirizine demonstrated an increased benefit over other antihistamines in terms of a more durable antihistamine response: levocetirizine provided improved symptom relief at 24 hours compared to desloratadine or fexofenadine, two frequently prescribed second-generation antihistamines. Levocetirizine also maintained relief of the key symptoms of allergic rhinitis and improved patients' QoL over a treatment period of 6 months, in a real-life setting. The variable efficacy and durability of response of different antihistamines arise from differing modulatory effects on the H1-receptor. The speed of relief of symptoms with levocetirizine is supported by the pharmacokinetic data, which shows that steady state plasma concentrations are achieved in a shorter period of time than other second-generation histamines (additionally levocetirizine Tmax is reached in 0.9 h).

Conclusion: These findings support both the short-term and long-term use of levocetirizine in the clinical management of allergic rhinitis. The World Health Organization (WHO) ARIA Guidelines (Allergic Rhinitis and its Impact on Asthma), recommend using a combination of a non-sedating antihistamine with a decongestant, or glucocorticosteroids for treating allergic rhinitis – with the order and combination of treatment depending on severity and duration of symptoms.

Keywords: ALLERGIC RHINITIS; ANTIHISTAMINES; DESLORATADINE; FEXOFENADINE; LEVOCETIRIZINE

Document Type: Commentary

DOI: 10.1185/030079905X53298

Affiliations: 1: Southampton General Hospital, and University of Southampton, Southampton, UK 2: Queens Medical Centre, Nottingham, UK 3: Sussex Allergy Service, Aldwick, West Sussex, UK 4: Surrey and Sussex NHS Trust, Cobham, Surrey, UK

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$31.50 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A